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TO THE EDITOR
Pemphigus and pemphigoid diseases
comprise a heterogeneous group of dis-
eases that are immunopathologically
characterized by autoantibodies against
structural proteins of the desmosome
and dermo–epidermal junction, respec-
tively. The clinical picture typically
shows blisters and erosions on the skin
and/or surface-close mucous mem-
branes (Stanley and Amagai, 2006;
Schmidt and Zillikens, 2013). Bullous
pemphigoid (BP) is the most frequent of
these diseases with a disease onset in
the late seventies and an incidence of
150–300/millions/year in the population
of 80 years and older (Langan et al.,
2008). Its incidence has at least doubled
in the last decade and the 1-year
mortality ranges from 20 to 40%,
which is about two to three times
higher compared with age- and sex-
matched controls (Langan et al., 2008;
Joly et al., 2012; Schmidt and Zillikens,
2013). Various case–control studies
revealed conflicting data about the asso-
ciation of BP with malignancies. Two
case–control studies 41,700 BP
patients from Sweden and Japan only
revealed a low association with gastric
cancer in the Japanese patients (Lindelo¨f
et al., 1990; Ogawa et al., 1995). In
contrast, numerous case reports
describe BP patients with various
associated malignancies, and recently
Ong et al. reported an increased risk of
BP in patients with kidney cancer,
laryngeal cancer, and leukemia (Ong
et al., 2014). Although no data about
malignancies are available for pemphi-
gus vulgaris and pemphigus foliaceus,
the association with malignancies is
undisputed in two rare autoimmune
blistering diseases, paraneoplastic
pemphigus, and anti-laminin 332
pemphigoid (Anhalt et al., 1990; Egan
et al., 2001; Bernard et al., 2013). The
aim of the present study was to
investigate the association between
autoimmune bullous diseases and
cancer in a large German cohort.
Data were extracted from the data-
base of a major health insurance com-
pany in Germany, the Techniker
Krankenkasse. All 8.3 million health-
insured subjects from 2008 to 2011
were analyzed on the basis of the ICD-
10-GM 2011 classification. Auto-
immune bullous disease patients’ data
were compared with an at least 5-fold
higher number of age- and sex-matched
controls randomly selected from the
database.
Initially, associations between each
disease and the 13 groups of malignan-
cies mentioned in chapter 3 of ICD-10
(C00-14, C15-26, C30-39, C40-41,
C43-44, C45-49, C50, C51-58, C60-
63, C64-68, C69-70, C73-75, and
C81-96) were analyzed. In case of sig-
nificance, a fine analysis was per-
formed. P-values were calculated by
Fisher’s exact test and confidence inter-
vals according to Wilson’s procedure.
An association of BP, pemphigus vul-
garis, and epidermolysis bullosa acqui-
sita with hematological malignancies
was observed (Table 1). Fine analyses
revealed Hodgkin disease (C81; OR 4.2
(1.90–8.9); Po0.01), non-follicular lym-
phoma (C83; OR 3.80 (1.90–7.5);
Po0.01), mature T/NK-cell lymphomas
(C84; OR 6.90 (3.1–16.0); Po0.001),
unspecified types of non-Hodgkin
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Table 1. Association of pemphigus and pemphigoid diseases with hematological malignancies
Patient characteristics Controls
OR (95% CI) P-value %1
Number Age (years) Median Sex ratio (f: m) Events Number Events
Bullous pemphigoid 1,743 71 1:1.17 117 10,141 275 2.55 (2.07–3.13) o 0.001 49
Pemphigus vulgaris 860 54 1.11:1 34 5,142 115 2.10 (1.40–3.03) 0.003 71
Pemphigus foliaceus 103 57 0.84:1 4 588 23 1.68 (0.48–4.78) 0.64 NA
Pemphigoid gestationis 126 33 n. a. 1 933 8 0.92 (0.06–4.63) 1 NA
Mucous membrane pemphigoid 251 63 1.9:1 3 1,386 40 0.50 (0.14–1.25) 0.25 NA
Epidermolysis bullosa acquisita 106 59 1.12:1 9 606 14 3.46 (1.48–7.66) 0.005 NA
Lichen sclerosus et atrophicans 27,021 55 4.5:1 504 158,329 2,812 1.05 (0.95–1.15) 0.33 45
Abbreviations: CI, confidence interval; f, female; m, male; NA, not applicable; OR, odds ratio.
1Percentage of patients, in whom the malignancy preceded the diagnosis of the autoimmune bullous disease.
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lymphoma (C85; OR 2.60 (1.60–3.9);
Po0.001), myeloid leukemia (C92; OR
5.70 (1.90–17.0); P¼0.01), and leuke-
mia of unspecified cell type (C95; OR
2.70 (1.40–5.1); P¼ 0.03) to be asso-
ciated with BP. Epidermolysis bullosa
acquisita was associated with mature T/
NK-cell lymphoma (C84; OR 72.42
(4.48–43,553.96); P¼0.03). Associa-
tions with non-hematological malignan-
cies are also shown in Table 2.
Lichen sclerosus, an inflammatory
dermatosis not mediated by autoanti-
bodies, served as control. While no
associations with hematological malig-
nancies are known for this disease,
cancer of genital organs and of the skin
frequently arises in lichen sclerosus
(Table 2).
Here we provide evidence for
increased frequencies of malignancies
in several autoimmune bullous diseases.
The percentages of patients with hema-
tological malignancies were 8.4%
among epidermolysis bullosa acquisita,
6.7% among BP, and 3.9% among
pemphigus vulgaris patients.
Latter association was previously
shown with paraneoplastic pemphigus
(Anhalt et al., 1990). However, pemphi-
gus vulgaris and paraneoplastic pemphi-
gus diseases are clearly differentiated by
ICD-10 codes (L10.0 and L10.8).
As in about half of the BP patients, the
hematological malignancy preceded the
diagnosis of BP, it appears unlikely that
the autoimmune disease had triggered
the malignancy. Interestingly, no asso-
ciation with non-hematological malig-
nancies was seen in BP. These data
support the results of two large case–
control studies (Lindelo¨f et al., 1990;
Ogawa et al., 1995) and indicate that
the assumption by numerous case
reports that reported such an asso-
ciation and our impression as treating
physicians may rather result from the
high rate of malignancies in this elderly
patient population.
Furthermore, oropharyngeal and
colon carcinomas were present in
0.9% and 3.7% of pemphigus vulgaris
patients, respectively. Of note, the two
carcinomas preceded the diagnosis of
pemphigus vulgaris in only 20% of
patients, indicating that the autoimmune
disease may have triggered the malig-
nancy (Table 2). This notion is somehow
corroborated by the observation that
pemphigus foliaceus (in which mucous
membrane are not involved) was not
associated with oropharyngeal and gas-
trointestinal malignancies. As pemphi-
gus foliaceus and vulgaris usually
receive the same immunosuppressive
therapy, it appears unlikely that the
carcinomas in pemphigus vulgaris were
triggered by the immunosuppressive
medication. However, in all other auto-
immune bullous diseases, no clear
temporal relationship with the malig-
nancies was observed favoring the idea
of a so far unknown immunological or
genetic third factor that triggers both the
malignancy and the autoimmune
disease.
Accordingly, an association with
malignancies of the eye and its adnexa
was only found in the single autoim-
mune bullous disease with potential eye
involvement––mucous membrane pem-
phigoid (Table 2). In fact, we and others
have previously described the occur-
rence of malignant tumors of the eye
with an ocular involvement in these
patients (Robinson et al., 2006;
Riederle et al., 2009).
Non-melanoma skin cancer was
linked with pemphigus foliaceus and
mucous membrane pemphigoid in
16.5% and 14.7% of patients, respec-
tively (Table 2). Interestingly, in most
patients, the skin cancer was diagnosed
before the autoimmune disease speak-
ing against the hypothesis that the ero-
sions, blisters, and the subsequent
regeneration process may have triggered
the skin cancer.
The validity of the ICD-10-derived
diagnoses was probed by data from
patients with pemphigoid gestationis
and lichen sclerosus. As expected, in
pemphigoid gestationis, a pemphigoid
disorder occurring during pregnancies
or the postpartum period (Schmidt and
Table 2. Association of pemphigus and pemphigoid diseases with non-hematological malignancies
Non-hematological malignancies (ICD-10) Events (patients) Events (controls) OR (95% CI) P-value %1
Pemphigus vulgaris
Oropharyngeal cancer (C10) 8 7 7.21 (2.68–19.9) o0.001 20
Gastrointestinal cancer (C15-C26) 53 143 2.56 (1.85–3.46) o0.001 NA
Colon cancer (C18) 32 78 2.44 (1.61–3.62) o0.001 21
Pemphigus foliaceus
Non-melanoma skin cancer (C44) 17 40 2.45 (1.43–4.04) 0.002 67
Mucous membrane pemphigoid
Non-melanoma skin cancer (C44) 37 113 1.80 (1.25–2.5) 0.001 69
Eye and adnexa cancer (C69) 7 0 11.47 (3.32–48.11) o0.001 NA
Lichen sclerosus et atrophicans
Cancer of female genital organs (C51–C58) 733 2,049 2.1 (1.93–2.28) o0.001 43
Cancer of male genital organs (C60–C63) 70 150 2.73 (2.04–3.61) o 0.001 63
Abbreviations: CI, confidence interval; NA, not applicable; OR, odds ratio.
1Percentage of patients, in whom the malignancy preceded the diagnosis of the autoimmune bullous disease.
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Zillikens, 2013), no associated malig-
nancy was observed. In contrast, in
lichen sclerosus, carcinomas of the
genitalia and the skin were revealed
(Powell and Wojnarowska, 1999). A
possible drawback of this study is its
reliance on the ICD-10 coding of
doctors from different specialities.
Although the large majority of auto-
immune bullous diseases are diagnosed
by dermatologists, coding of these
disorders by non-dermatologists might
have led to mistakes. On the basis of the
coding of pemphigoid gestationis in one
man and four female patients older than
50 years, the false-coding rate was
estimated to be 4%.
The present findings will be relevant
for the future care of patients with
autoimmune bullous disorders. Regard-
less of the reason for the higher inci-
dence of cancer in some of these
diseases, an increased awareness in com-
bination with regular differential blood
counts and inspection of the entire skin,
as well as routinely performed gastro-
and coloscopy in patients with pemphi-
gus vulgaris might be helpful to detect
the associated malignancies as early as
possible in the majority of patients.
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TO THE EDITOR
The Kindler syndrome (KS; OMIM173650)
is a rare autosomal recessive disorder
characterized by trauma-induced blis-
tering, cutaneous atrophy, and progres-
sive poikiloderma, in association with
mucosal inflammation (Kindler, 1954;
Lai-Cheong and McGrath, 2010; Has
et al., 2011). Some individuals also
suffer from photosensitivity, which tends
to lessen with advancing age. Marked
skin atrophy, the hallmark of the disease,
develops early in life particularly on the
dorsal aspects of the hands and feet and
becomes generalized in most cases
by adolescence. Other clinical features
include mucosal stenosis, gastrointe-
stinal symptoms, and increased risk for
non-melanoma skin cancer, with deve-
lopment of squamous cell carcinomas
in acral skin and the mouth with
considerable phenotypic variability
(Cardin-Langlois et al., 2010; Has
et al., 2010; Lai-Cheong and McGrath,
2010; Has et al., 2011). Histopathology
of the skin shows hyperkeratosis, epi-
dermal atrophy, loss of rete ridges, and
focal vacuolization of the basal layer
of the epidermis, consistent with poiki-
loderma. Transmission electron micro-
scopy of the non-blistered skin demon-
strates reduplication of the basal lamina
with focal interruptions of the lamina
densa, a diagnostic feature that can be
demonstrated by immunofluorescence
staining of the skin with an anti-type IV
or type VII collagen antibody or by
transmission electron microscopy.Accepted article preview online 19 January 2015; published online 5 March 2015
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